SHZ:002393

Tianjin Lisheng Pharmaceutical Co.,Ltd. · SHZ · Healthcare · CNY · FY for 2025

Figures on this page computed 2026-11-08 13:31 UTC

Last close

n/aCNY

Market data

8.0xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
CNY
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
30.0%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
29.8%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
2.7%Dividend yield
Source
computed
Taken on
2026-11-08
Reported in
CNY
- computed

6 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

All from 100

lens 2 of 9

Sales

164

2016-12-31 to 2025-12-31100 at the start164

Sales: 100.00 on 2016-12-31 to 164.45 on 2025-12-31, up 64%.

Profit

362

2016-12-31 to 2025-12-31100 at the start362

Profit: 100.00 on 2016-12-31 to 361.89 on 2025-12-31, up 262%.

Shares in issue

101

2016-12-31 to 2025-12-31100 at the start101

Shares in issue: 100.00 on 2016-12-31 to 100.52 on 2025-12-31, up 1%.

Sales is at 164, Profit is at 362, Shares in issue is at 100, against 100 in 2016.

Sales is at 164, Profit is at 362, Shares in issue is at 100, against 100 in 2016.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales, where the first year is 100165
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Profit, where the first year is 100362
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Shares in issue, where the first year is 100101
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY